PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19784551-12	2010	Since TAE226 has been shown to inhibit the PI3 kinase, Akt kinase, mTor pathway, addition of RAD001 may not increase this effect.	TAE226	6-12	mechanistic target of rapamycin kinase	Homo sapiens	67-71	
19020730-0	2008	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	71-75	
19020730-6	2008	The purpose of this study was to explore the inhibitory effects on mTOR signaling and the mechanism of cell growth suppression by TAE226.	TAE226	130-136	mechanistic target of rapamycin kinase	Homo sapiens	67-71	
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	35-39	
19020730-9	2008	TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244).	TAE226	0-6	mechanistic target of rapamycin kinase	Homo sapiens	94-98	
19020730-11	2008	Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.	TAE226	31-37	mechanistic target of rapamycin kinase	Homo sapiens	71-75	
19020730-11	2008	Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.	TAE226	136-142	mechanistic target of rapamycin kinase	Homo sapiens	71-75